NIKKEI 225
38,179.46 -49.65 (-0.13%) HANG SENG
19,115.06 +151.38 (+0.80%) CRUDE OIL
78.70 +0.44 (+0.56%) GOLD FUTURES
2,341.80 -33.20 (-1.40%) DOW
39,444.52 -68.32 (-0.17%) Bitcoin GBP
50,058.13 +1,114.69 (+2.28%)
Disc Medicine, Inc. (IRON)
| Previous close | 30.36 |
| Open | 30.81 |
| Bid | 31.51 x 100 |
| Ask | 32.02 x 100 |
| Day's range | 30.81 - 32.33 |
| 52-week range | 25.60 - 77.60 |
| Volume | |
| Avg. volume | 493,583 |
| Market cap | 784.172M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
WATERTOWN, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Monday, May 20th at 10:30 am ET. A live webcast of the fireside chat will be available through the
- GlobeNewswire
Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
Presented top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), in April 2024On track to deliver additional analyses from BEACON and AURORA in Q2 2024Plan to present updated data from the phase 1b/2 study of DISC-0974 in anemia of myelofibrosis (MF), as well as initial single-ascending dose (SAD) data from the phase 1 study of DISC-3405 in healthy volunteers in Q2 2024Continue to be well-capitalized, ending Q1 2024 with $343M in cash
- GlobeNewswire
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
Met primary endpoint, demonstrating dose-dependent, statistically significant reductions in protoporphyrin IX (PPIX) compared to placebo in both 20 mg and 60 mg dose groupsImproved measures of light tolerance, including the key secondary endpoint, in both 20 mg and 60 mg dose groups, but did not meet statistical significance compared to placeboDose-dependent reductions in the rate of phototoxic reactions with pain, with statistical significance at the 60 mg dose group compared to placeboDose-dep
